|

CD19/BCMA Targeted CAR T-cells and dasatinib Clinical Trials

1 actively recruiting trial

Also known as: Administration of CD19/BCMA Targeted CAR T-cells and dasatinib

Pipeline

Early 1: 1

Top Sponsors

  • Zhejiang University1

Indications

  • Non-Hodgkin's Lymphoma Refractory1
  • Non-Hodgkin's Lymphoma, Relapsed1
  • Acute Lymphocytic Leukaemia Refractory1
  • Multiple Myeloma, Refractory1
  • Multiple Myeloma in Relapse1

Other1 trial

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.